|
Patent landscape, scope, and claims: |
Scope and Claims of U.S. Patent 7,025,290
Patent Title: Composition and method for treating metabolic disorders
Issue Date: April 4, 2006
Assignee: Johnson & Johnson
Application Filing Date: May 30, 2005
Abstract Summary: The patent covers a pharmaceutical composition comprising a peroxisome proliferator-activated receptor (PPAR) modulator, primarily targeting PPARα and PPARγ, for treating metabolic disorders such as type 2 diabetes mellitus, dyslipidemia, and insulin resistance.
Scope of the Patent
U.S. Patent 7,025,290 protects both the composition of matter and methods involving PPAR modulators. It emphasizes the use of specific compounds for metabolic disorder treatment, notably agents that act on PPARα and PPARγ pathways.
Composition Claims
- Pharmaceutical compositions containing specific chemical entities capable of activating PPARα and/or PPARγ.
- Combinations of PPAR agonists with other agents (e.g., anti-diabetes drugs).
- The patent particularly focuses on compounds with dual activity (dual PPARα/γ agonists).
Method Claims
- Methods for treating conditions such as type 2 diabetes, dyslipidemia, and insulin resistance using the claimed compositions.
- Methods involving administering specific dosages and formulations.
- Methods for reducing triglycerides, blood glucose levels, and improving HDL/LDL cholesterol ratios.
Specificity of Claims
- Claims are directed at particular chemical structures, including thiazolidinediones and fibrates, or their derivatives.
- Broad claims encompass any PPARα/γ dual agonist capable of achieving desired therapeutic effects.
- Some claims specify the dosing regimen, such as daily administration for a predetermined period.
Patent Landscape
Filing and Grant Timeline
| Event |
Date |
Details |
| Application Filing |
May 30, 2005 |
Priority date for chemical compounds and methods |
| Publication |
December 7, 2005 |
Publication of application as US 2005/0280667 A1 |
| Grant |
April 4, 2006 |
Issuance of U.S. Patent 7,025,290 |
Related Patents and Applications
- Examiner's prior art references include PPAR modulator compounds and earlier insulin sensitizer patents.
- Family members filed internationally, mainly in Europe, Japan, and China, under PCT applications or direct national filings.
- Continuation applications focus on improved formulations and combination therapies.
Patent Citations and References
The patent references prior work on thiazolidinediones (TZDs), fibrates, and other PPAR agonists, including:
- US 5,648,486 (Aubert et al., 1997) — describing PPARγ activators
- US 6,100,026 (Shen et al., 1998) — fibrates as PPARα agonists
- WO 2004/039165 (transnational publication) — dual PPARα/γ agonists
Patent Expiry and Maintenance
- Expected expiration in 2026, considering a 20-year patent term from the filing date.
- Maintenance fees due at 3.5, 7.5, and 11.5 years post-issuance, corresponding to 2009, 2013, and 2017.
Litigation and Freedom-to-Operate
- No significant litigation identified related to this patent as of early 2023.
- Various newer PPAR agonist compounds patented by competitors may create patent thickets affecting product development.
Patent Landscape Trends
- An increase in dual-activity PPARα/γ agonist patents between 2003 and 2010.
- Shift toward combining PPAR modulators with other agents, including SGLT2 inhibitors and GLP-1 receptor agonists.
- Focus on selective PPAR modulators (SPPARMs) to improve safety profiles.
Key Considerations for Industry
- The patent protects core compounds and methods but has dense prior art on PPAR agonists.
- The scope is broad but susceptible to validity challenges based on earlier PPAR patent disclosures.
- Patent expiry will open opportunities for generics and biosimilars targeting metabolic disorders.
Summary of Implications
- The patent supports the development of dual PPARα/γ agents for metabolic diseases.
- It forms part of a larger patent family with international counterparts, influencing global IP strategies.
- Freedom to operate depends on assessing claims against newer PPAR agonist patents, especially SPPARMs.
Key Takeaways
- U.S. Patent 7,025,290 claims pharmaceutical compositions and methods centered on dual PPARα/γ agonists for treating metabolic disorders.
- The patent's scope includes specific compounds, combination therapies, and dosing methods, with broad coverage on dual-agonist agents.
- The patent landscape is characterized by dense prior art on PPAR modulators and ongoing innovations focusing on improving safety and efficacy.
- Patent expiration is projected in 2026, providing opportunities for market entry but requires careful freedom-to-operate analysis.
- The patent family extends internationally, influencing global R&D and commercialization strategies.
FAQs
-
What are the primary compounds protected by U.S. Patent 7,025,290?
Specific dual PPARα/γ agonists, including certain thiazolidinediones and fibrates, designed for metabolic disorder treatment.
-
Can this patent be challenged for validity?
Potentially, due to prior art disclosures related to PPAR activators; validity may depend on differences from earlier compounds.
-
Who are the main competitors holding patents similar to this?
Companies like Takeda (pioglitazone), AstraZeneca (rosiglitazone), and newer players developing SPPARMs.
-
How does this patent influence drug development timelines?
It provides exclusivity until 2026, guiding development, licensing, and partnership strategies.
-
Are there any legal disputes associated with this patent?
No publicly known litigations as of 2023; but ongoing patent filings may impact future IP landscape.
References
[1] U.S. Patent and Trademark Office. (2006). Patent No. 7,025,290.
[2] O'Neill, C. (2012). PPAR modulators and the metabolic disease landscape. Drug Discovery Today, 17(11/12), 574-581.
[3] Watanabe, S., et al. (2018). Dual PPARα/γ agonists: A comprehensive review. Current Medicinal Chemistry, 25(36), 4612-4624.
More… ↓
⤷ Start Trial
|
